Get the Stockscreener App
46.73
0.39%
0.18
Crinetics Pharmaceuticals Inc stock is traded at $46.73, with a volume of 680.31K.
It is up +0.39% in the last 24 hours and up +3.82% over the past month.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
See More
Previous Close:
$46.55
Open:
$46.62
24h Volume:
680.31K
Relative Volume:
0.53
Market Cap:
$4.43B
Revenue:
$4.72M
Net Income/Loss:
$-277.91M
P/E Ratio:
-12.53
EPS:
-3.73
Net Cash Flow:
$-203.56M
1W Performance:
-2.56%
1M Performance:
+3.82%
6M Performance:
+58.73%
1Y Performance:
-9.35%
1-Day Range:
$45.51
$47.05
1-Week Range:
$45.51
$48.25
52-Week Range:
$24.10
$53.55
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Name
Crinetics Pharmaceuticals Inc
Sector
Industry
Phone
858-450-6464
Address
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
46.73 | 4.42B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Initiated | Goldman | Neutral |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-11-25 | Initiated | TD Cowen | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Peer Perform |
| Jan-22-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Jan-16-24 | Initiated | Morgan Stanley | Overweight |
| Dec-21-23 | Initiated | Jefferies | Hold |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-31-23 | Initiated | Oppenheimer | Outperform |
| Apr-24-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Robert W. Baird | Outperform |
| Nov-30-21 | Initiated | JMP Securities | Mkt Outperform |
| Nov-23-21 | Initiated | Evercore ISI | Outperform |
| Jun-18-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-23-19 | Initiated | ROTH Capital | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Aug-13-18 | Initiated | JP Morgan | Neutral |
| Aug-13-18 | Initiated | Leerink Partners | Outperform |
| Aug-13-18 | Initiated | Piper Jaffray | Overweight |
View All
Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News
Moody Aldrich Partners LLC Trims Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Investors in Crinetics Pharmaceuticals (NASDAQ:CRNX) Have Seen Impressive Returns of 234% Over the Past Five Years - 富途牛牛
Aug Macro: Will Crinetics Pharmaceuticals Inc stock outperform growth indexesMarket Activity Report & High Accuracy Investment Entry Signals - moha.gov.vn
174,077 Shares in Crinetics Pharmaceuticals, Inc. $CRNX Purchased by Rice Hall James & Associates LLC - MarketBeat
Crinetics Pharmaceuticals Earnings Notes - Trefis
(CRNX) Risk Channels and Responsive Allocation - Stock Traders Daily
Crinetics Pharmaceuticals (CRNX): Assessing Valuation After a 36% Three-Month Share Price Rebound - Sahm
Crinetics Pharmaceuticals (FRA:6Z4) EV-to-OCF : -9.65 (As of Dec. 23, 2025) - GuruFocus
Squarepoint Ops LLC Has $1.21 Million Stake in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
CEO Change: Will ZVRA stock split again soon2025 Momentum Check & Verified Momentum Watchlists - moha.gov.vn
Will Crinetics Pharmaceuticals Inc. stock benefit from green energy trendsWeekly Stock Recap & Free Weekly Watchlist of Top Performers - Улправда
Why Crinetics Pharmaceuticals Inc. stock is a value investor pickMarket Sentiment Summary & Weekly Top Gainers Alerts - Улправда
Will Crinetics Pharmaceuticals Inc. stock recover faster than peersRecession Risk & Free Fast Gain Swing Trade Alerts - Улправда
Is Crinetics Pharmaceuticals Inc. stock attractive for hedge fundsLayoff News & Fast Exit and Entry Strategy Plans - Улправда
What risks investors should watch in Crinetics Pharmaceuticals Inc. stockMarket Sentiment Report & Fast Entry Momentum Trade Alerts - Улправда
Aug Volume: Will Crinetics Pharmaceuticals Inc. stock benefit from green energy trends2025 Stock Rankings & Accurate Buy Signal Alerts - Улправда
Does Crinetics Pharmaceuticals Inc. stock trade at a discount to peersJuly 2025 Intraday Action & Consistent Profit Focused Trading Strategies - DonanımHaber
Is Crinetics Pharmaceuticals Inc. stock overvalued by current metricsWeekly Profit Analysis & Risk Controlled Stock Pick Alerts - DonanımHaber
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Can Crinetics Pharmaceuticals Inc. (6Z4) stock sustain revenue momentumJuly 2025 Retail & Step-by-Step Trade Execution Guides - DonanımHaber
Crinetics Pharmaceuticals CEO Scott Struthers to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 7.9%Here's Why - MarketBeat
Crinetics Pharmaceuticals (CRNX) Stock Drops After CMO Departure Filing: Latest News, Analyst Forecasts, and What’s Next (Dec. 18, 2025) - ts2.tech
Crinetics Pharmaceuticals stock falls after CMO departure announcement By Investing.com - Investing.com South Africa
Crinetics Pharmaceuticals stock falls after CMO departure announcement - Investing.com
Crinetics Pharmaceuticals Shares Fall After Chief Medical, Development Officer Steps Down - marketscreener.com
Why Crinetics Pharmaceuticals Shares Are Sinking Today - TipRanks
How Crinetics Pharmaceuticals Inc. stock trades during market volatilityEarnings Miss & Technical Confirmation Trade Alerts - Улправда
[8-K] Crinetics Pharmaceuticals, Inc. Reports Material Event | CRNX SEC FilingForm 8-K - Stock Titan
Crinetics Pharmaceuticals, Inc. Announces Resignation of Dana Pizzuti as Chief Medical and Development Officer, Effective from December 31, 2025 - marketscreener.com
What is HC Wainwright's Estimate for CRNX FY2025 Earnings? - MarketBeat
Sanders Morris Harris LLC Takes Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
What is HC Wainwright's Estimate for CRNX FY2028 Earnings? - MarketBeat
Will Crinetics’ (CRNX) First SST2 NDC Trial and Atumelnant Milestone Reframe Its Pipeline Narrative? - simplywall.st
Crinetics Pharmaceuticals Inc (CRNX) - MSN
CRNX stock touches 52-week low at $35.47 amid market shifts - MSN
Does Crinetics Pharmaceuticals Still Offer Value After Its Recent Share Price Rebound? - Yahoo Finance
Trading the Move, Not the Narrative: (CRNX) Edition - news.stocktradersdaily.com
Crinetics Pharmaceuticals (CRNX) Valuation Check After First-Patient Dosing in New SST2 Tumor Trial - Sahm
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) - Koreabizwire
Crinetics Pharmaceuticals Doses First Patient in Phase 3 Trial of Atumelnant for Classic Congenital Adrenal Hyperplasia - Quiver Quantitative
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital ... - Enidnews.com
Crinetics Pharmaceuticals (CRNX) poised for transformational growth in 2026: Piper Sandler - MSN
Crinetics Pharmaceuticals (CRNX) Poised for Transformational Growth in 2026: Piper Sandler - Yahoo Finance
Crinetics Pharmaceuticals, Inc. (CRNX) Poised for Transformational Growth in 2026: Piper Sandler - Insider Monkey
15 Best Biotech Stocks to Buy According to Wall Street Analysts - Insider Monkey
Crinetics (NASDAQ: CRNX) doses first patient in Phase 3 CALM-CAH trial of atumelnant - Stock Titan
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Crinetics (Nasdaq: CRNX) issues 39,575 options, 26,525 RSUs to 9 new hires - Stock Titan
JPMorgan Chase & Co. Has $9.55 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharmaceuticals Inc Stock (CRNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Crinetics Pharmaceuticals Inc Stock (CRNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Betz Stephen F. | Chief Scientific Officer |
Dec 26 '25 |
Option Exercise |
1.91 |
18,000 |
34,380 |
117,713 |
| Struthers Richard Scott | President & CEO |
Dec 18 '25 |
Option Exercise |
13.09 |
44,742 |
585,890 |
364,759 |
| Pizzuti Dana | Chief Med and Dev Officer |
Dec 01 '25 |
Option Exercise |
16.89 |
5,000 |
84,450 |
71,837 |
| Pizzuti Dana | Chief Med and Dev Officer |
Dec 01 '25 |
Sale |
45.02 |
5,000 |
225,100 |
66,837 |
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):